Key Highlights

• Statutory results swung to a net loss of about US$2.6 billion.

• The gap reflects roughly US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs.

• The company also said its transformation program delivered about US$176 million of savings in FY26, ahead of a US$100 million target.

• Management indicated further savings in FY27, with about half expected to be reinvested.

What does a multibillion-dollar statutory loss mean for CSL (ASX:CSL), and why has the market focused on the underlying Business instead? The short answer is that the loss reported for the year to 30 June 2026 was driven largely by non-cash impairments and restructuring, while underlying Earnings were broadly steady and the company guided to modest growth for FY27. The harder questions now concern how quickly its core plasma business can recover and who will lead it.

The central development: a reset year

CSL reported its FY26 results on 18 August 2026. Statutory results swung to a net loss of about US$2.6 billion.

The gap reflects roughly US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs. The largest part of the impairments related to the Vifor business, including Goodwill and product intangibles, with the remainder relating mainly to property, plant and equipment. These are largely accounting charges, but they signal lowered expectations for parts of the portfolio.

The company also said its transformation program delivered about US$176 million of savings in FY26, ahead of a US$100 million target. Management indicated further savings in FY27, with about half expected to be reinvested.

What CSL does and how it earns

CSL is a global biotechnology group with three main segments.

CSL Behring, the largest at about US$11.4 billion of FY26 revenue, collects human plasma and manufactures plasma-derived therapies. These include immunoglobulins (Ig), albumin and treatments for rare bleeding disorders, alongside newer products such as Andembry and Hemgenix. Ig sales were flat at about US$6.2 billion for the year.

CSL Seqirus, which makes influenza vaccines, generated about US$2.0 billion, down 8 per cent, partly because of non-recurring avian influenza revenue.

CSL Vifor, focused on iron deficiency and nephrology products, generated about US$2.4 billion, up 3 per cent.

Plasma Supply is a defining feature of the model. CSL operates one of the largest collection networks globally, so collection costs per litre and centre productivity directly influence Behring's margins.

FY27 guidance

Management guided, at constant currency, to broadly flat group Revenue and underlying NPAT growth of about 5 per cent, excluding restructuring and Impairment items. This is company guidance, not a forecast of outcomes.

The segment detail matters more than the headline:

• Behring is expected to deliver mid-single-digit revenue growth, with Ig growing faster, and a gross Margin recovery.

• Seqirus is guided to low-single-digit growth, assuming US immunisation rates decline more slowly than in recent seasons.

• Vifor revenue is expected to fall about 25 per cent, reflecting generic iron competition and the end of a Velphoro reimbursement benefit on 31 December 2026.

In other words, Behring must offset a substantial drag from Vifor.

Capital management and governance

The final Dividend was US$1.62, taking the full-year dividend to US$2.92 per share, maintained in US dollars. CSL also announced on 26 August 2026 an on-market buy-back of up to A$1.15 billion, running from 10 September 2026 to 30 June 2027.

On leadership, Gordon Naylor is Interim CEO and Managing Director, and the board has said its search for a permanent chief executive is well advanced. The Annual General Meeting was scheduled for 27 October 2026 in Melbourne, with Mr Naylor standing for election as a director. The chair acknowledged Shareholder frustration with FY26 performance in the notice of meeting.

On Seqirus, management reportedly said the operational separation is complete but that no near-term demerger is planned, although the option remains open.

Sector conditions and competition

The plasma industry has been working through post-pandemic normalisation, including changes in US sales channels, which weighed on Ig revenue in FY26. Management said Ig grew in the second half compared with the prior year, which supports the case for recovery but is a short period.

Competition is a live issue. Another longer-term question is whether newer complement-inhibitor therapies could take Volume from Ig in some conditions. Readouts from argenx and Dianthus studies are being watched, with the first argenx data cited for the fourth quarter of calendar 2026. These are estimates and timelines, and trial outcomes are uncertain.

Seqirus operates in a flu Vaccine market where US vaccination rates have been falling.

Key risks and what to watch

• Execution risk: Behring's margin recovery depends on lowering plasma costs and delivering savings without disrupting supply.

• Vifor decline: a steep fall in FY27 revenue leaves less room for error elsewhere.

• Albumin weakness in China and possible channel inventory effects.

• Competition from rival subcutaneous Ig products and from emerging therapies.

• Influenza vaccine Demand in the United States.

• Leadership transition until a permanent CEO is named.

• Currency movements, as CSL reports in US dollars while listed in Australia.

Bottom line

CSL's FY26 result separated a large accounting reset from steadier underlying earnings. The Investment debate now centres on whether Behring's Ig recovery and cost savings can outweigh Vifor's decline and a changing competitive landscape. Those are uncertainties, not takeaways, and outcomes may differ from guidance.